Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study
There were no particular safety issues as reported in the phase 2/3 study and no clear deterioration in survival rate or physical function when ultra-high-dose methylcobalamin was administered intramuscularly in patients with advanced ALS. This regimen could be a candidate for initial therapy with further add-on to overcome ALS in the future.
Authors
- Ryuji Kaji (ORCID: https://orcid.org/0000-0001-6207-1080)
- Takao Takase (ORCID: https://orcid.org/0000-0002-4556-5035)
- Yuishin Izumi (ORCID: https://orcid.org/0000-0002-3048-9041)
- Takayuki Ishida (ORCID: https://orcid.org/0000-0003-1690-3899)
- Yurie Nishi
- T. Maeda
- Tamon Ueda
Institutions
- Eisai (Japan) (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Journal of the Neurological Sciences
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1016/j.jns.2025.125701
- Citations
- 3
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 4.17